ANGLE
FY21 results: prepared for commercial successFutura Medical
FY21 results reassure on cash runway and hint at EU dealArecor Therapeutics
Ambitious, focussed, and delivering on its promiseScancell
A fresh impetus in delivering immune-oncology vaccinesMaxCyte
Sustained FY21 growth with significantly more potentialAvacta
FY21 results: a year of frustrations and opportunitiesRedx Pharma
RXC008 nominated as GI-ROCK drug candidateFutura Medical
Menarini to commercialise MED3000 in South KoreaMaxCyte
Opening the next chapterHUTCHMED
A genuinely global R&D-driven biopharma business